Adoption: Attachment & Bonding
Adoption: Coping & Support
Adoption: Expecting Through Adoption
Adoption: Exploring Adoption
Adoption: Finances and Funding
Art Resources & Reading
Contact Us
Discipline and Behavior
Discussion Forums
Feeding and Nutrition
Fertility 101
Fertility Preservation
Genetic Testing
Grief & Loss
Highlights from the ASRM
Infertility & Alternative Treatments
Infertility & Cancer: What now?
Infertility & the Environment
Infertility and PGD Testing
Infertility Basics
Infertility Coping, Support &
Success Stories

Infertility, Donor & 3rd Party Reproduction
Infertility: Complementary Medicine
Infertility: Making the Decision to Live Childfree
Infertility: Male Factor
Infertility: Reproductive Immunology & Implantation failure
Insurance Basics
Insurance, Statistics, IVF and More
Insurance: Carriers that may Offer Infertility Coverage
Insurance: Legal Issues and Reproduction or Adoption
Insurance: Programs & Mandates
Insurance: Understanding Insurance
Legal Disclaimer: Legal Terms for Use
Make a Dream Come True Heart Teams
Meet Our Sponsors
Memorial Gardens
Memorial Gardens
Miscarriage & Pregnancy Loss
Newly Pregnant
Newsletters & Other Announcements
Parenting After
Parenting Coping & Support
Parenting in the NICU
Parenting the Special Needs Child
Parenting: Breastfeeding
Pediatrics, Childhood Illness & Sleep Issues
Pregnancy After 40
Pregnancy After Loss
Pregnancy Coping & Support
Pregnancy Loss Coping & Support
Pregnancy: High Risk
Press Room
Professionals and Providers
Programs & Initiatives
Site Map
Stages of Pregnancy
Support & Advocacy
Support Us
Surveys, Studies and Polls
Women's Health Coping & Support
Women's Health: Lifestyles

News » Press Room

August 13, 2002 - 7:31 PM by Nicole Lewis
Views: 7411

FOLLISTIM™ (follitropin beta for injection) is the first recombinant follicle-stimulating hormone (FSH) to receive clearance in the United States for the induction of ovulation in women experiencing anovulation (an absence of ovulation) and in women undergoing assisted reproductive technology (ART) procedures.

FOLLISTIM™ is a highly purified preparation, with a high level of manufacturing consistency.

These advantages result in a reliable and increased supply of this hormone preparation that can be administered subcutaneously and that has a higher specific activity than other FSH agents, such as urofollitropin and menotropin.

FOLLISTIM™ was studied in the world’s largest randomized in vitro fertilization (IVF) study ever conducted.(1) The study included 981 women undergoing IVF at 18 centers throughout Europe. The results demonstrated that FOLLISTIM™ is safe and effective as compared to urofollitropin, the most widely used FSH treatment in the U.S. during 1996.

FOLLISTIM™ acts like naturally produced FSH by stimulating the development of follicles within the ovary. It binds to the FSH receptors located on the surface of small granulosa cells surrounding the immature follicle and oocyte.

Although FOLLISTIM™ acts to stimulate the maturation of follicles, it does not induce ovulation. For ovulation to occur, therapy with FOLLISTIM™ is followed by a single administration of 5,000 to 10,000 IU of human chorionic gonadotropin (hCG).

The dosage range for FOLLISTIM™ is 150 IU to 600 IU daily, depending on the patient response. FOLLISTIM™ may be administered either subcutaneously or intramuscularly.

Adverse Effects

Although FOLLISTIM™ may cause certain adverse effects, the incidence of these events is relatively low and similar to that of other FSH-containing infertility products.

The following adverse events occurred in one percent or more of the patients treated with FOLLISTIM™ during clinical trials and are similar in type and frequency to those that occurred with urofollitropin:

  • Ovarian hyperstimulation syndrome (OHSS 5.2%)
  • Miscarriage (3.2%)
  • Ectopic pregnancy (2.2%)
  • Abdominal pain (1.9%)
  • Vaginal hemorrhage (1.1%)
  • Injection site pain (1.0%)

The following adverse events occurred in less than one percent of the patients treated with FOLLISTIM™ during clinical trials and are similar in type and frequency to those that occurred with urofollitropin:

  • Ovarian cysts
  • Mild to moderate ovarian enlargement
  • Body rashes

(1) “A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone in in-vitro fertilization,” Human Reproduction, vol.10 no.10 pp. 2534-2540, 1995.

  • John J. Seng
  • David Sheon

(202) 955-6222

Source: Organon Pharmaceuticals

Thread User # Posts Post Date

Powered by: Miraserver v.1.0
Copyright 2003, PC Media, Inc.
10 database queries total
Execution time = 0.163535 seconds
Cached: No